You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
熱景生物(688068.SH):擬出資2600萬元參設禹景藥業 探索活菌藥物研發領域
格隆匯 02-15 18:14

格隆匯2月15日丨熱景生物(688068.SH)公佈,為開拓公司業務需求,基於公司深厚的研發技術積累,深化公司從診斷到治療的戰略方向佈局,公司擬探索活菌藥物研發領域,以進一步優化公司業務結構,提升公司的持續競爭能力;同時通過實際控制人及關鍵管理人員參與的方式,分擔投資風險並實現相應激勵。

公司擬與董事長、總經理林長青,以及員工持股平台堯景管理中心共同出資5000萬元人民幣設立北京禹景藥業有限公司(簡稱“禹景藥業”,最終名稱以工商登記為準),其中公司擬以自有資金出資人民幣2600萬元,佔禹景藥業註冊資本的52.00%;林長青出資人民幣1,900萬元,佔禹景藥業註冊資本的38.00%;北京堯景企業管理中心(有限合夥)出資人民幣500萬元,佔禹景藥業註冊資本的10.00%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account